Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupGastroenterologic OncologyRegional therapyDiseaseColon CancerSubgroupICD10C18.0C18.2C18.3C18.4C18.5C18.6C18.7C18.8C19MeSHColonic NeoplasmsColorectal NeoplasmsSequenceChemotherapyChemo-substanceDrug-Eluting BeadsIodixanolIrinotecanChemo-substanceDrug-Eluting BeadsIodixanolIrinotecanChemo-substanceDrug-Eluting BeadsIodixanolIrinotecanChemo-substanceDrug-Eluting BeadsIodixanolIrinotecanNo. Substances3 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronNo. Substances3Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentionpalliativeRisksEmetogenicity (MASCC/ESMO) only studiesPublicationAuthorArnold DDiseaseKolorektales Karzinom mit Lebermetastasen, ECOG 0-3OriginAsklepios Tumor Centre Hamburg, AK Altona, Hamburg; CIREL studyProtocols in Revision 1 protocol foundProtocols under revision.DEB-TACE - Irinotecan 100, Colorectal Carcinoma (PID2877 V1.0)